Paradoxical decrease in high-density lipoprotein-cholesterol associated with statin-fenofibrate combination therapy [1]

British Journal of Diabetes and Vascular Disease

Volumn 8, Issue 1, 2008, Pages 5-

  Hulme, Shirley ^a   O'Brien, Sarah ^b   Cardwell, Janet ^b   McNulty, Sid ^b   Hardy, Kevin ^b  

^a WHISTON HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

COMBINATION CHEMOTHERAPY; DRUG WITHDRAWAL; EVENING DOSAGE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LETTER; LOGISTIC REGRESSION ANALYSIS; MICROALBUMINURIA; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; STROKE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 41349093184     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514080080010301     Document Type: Letter

References (2)

1. J Glaysher, C Van Heyningen. Paradoxical decrease in high-density lipoprotein-cholesterol associated with statin and fenofibrate combination therapy. Br J Diabetes Vasc Dis 2007;7:295-7.
2. Marsh J, Hulme S, O'Brien S, McNulty S, Hardy K. Heterogeneous HDL-C response to fenofibrate therapy in diabetes. Diabetic Med 2004; 21 (suppl2):A61.